Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGULUS THERAPEUTICS INC.

(RGLS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Regulus Therapeutics : CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF (Form 8-K)

06/16/2021 | 04:04pm EDT

CERTIFICATE OF AMENDMENT OF THE

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

OF

REGULUS THERAPEUTICS INC.

REGULUS THERAPEUTICS INC., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the 'Company'), does hereby certify:

FIRST: The name of the Company is Regulus Therapeutics Inc.

SECOND: The date on which the Company's original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware is January 2, 2009.

THIRD: The Board of Directors of the Company (the 'Board'), acting in accordance with the provisions of Sections 141 and 242 of the General Corporation Law of the State of Delaware (the 'DGCL'), adopted resolutions approving and deeming advisable an amendment to the Company's Amended and Restated Certificate of Incorporation (the 'Restated Certificate'), as follows:

Paragraph A of Article IV of the Restated Certificate is hereby amended and restated to read in its entirety as follows:

'A. The Company is authorized to issue two classes of stock to be designated, respectively, 'Common Stock' and 'Preferred Stock.' The total number of shares which the Company is authorized to issue is 410,000,000 shares. 400,000,000 shares shall be Common Stock, each having a par value of $0.001. 10,000,000 shares shall be Preferred Stock, each having a par value of $0.001.'

FOURTH: The foregoing amendment was submitted to the stockholders of the Company for their approval, and was duly adopted in accordance with the provisions of Section 242 of the DGCL.

FIFTH: This Certificate of Amendment shall become effective on June 14, 2021 at 4:00 p.m. Eastern Time.

IN WITNESS WHEREOF, Regulus Therapeutics Inc. has caused this Certificate of Amendment to be signed by its President and Chief Executive Officer on June 14, 2021.

Regulus Therapeutics Inc.
By:

/s/ Joseph Hagan

Joseph Hagan
President and Chief Executive Officer

1

Disclaimer

Regulus Therapeutics Inc. published this content on 16 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 June 2021 20:03:08 UTC.


ę Publicnow 2021
All news about REGULUS THERAPEUTICS INC.
06/25REGULUS THERAPEUTICS : Presents Additional Data from its Autosomal Dominant Poly..
PR
06/25Regulus Therapeutics Presents Additional Data from its Autosomal Dominant Pol..
CI
06/21REGULUS THERAPEUTICS : to Present Additional Data from its Autosomal Dominant Po..
PR
06/21Regulus Therapeutics Inc. to Present Additional Data from Its Autosomal Domin..
CI
06/16REGULUS THERAPEUTICS : CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERT..
PU
06/16REGULUS THERAPEUTICS INC. : Amendments to Articles of Inc. or Bylaws; Change in ..
AQ
05/21REGULUS THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (for..
AQ
05/21Regulus Therapeutics Inc. Announces Incremental Update of Autosomal Dominant ..
CI
05/14REGULUS THERAPEUTICS : to Present at the Oppenheimer Rare & Orphan Disease Summi..
PR
05/14REGULUS THERAPEUTICS : Wedbush Halves Regulus Therapeutics' PT to $1 From $2 on ..
MT
More news
Financials (USD)
Sales 2021 0,03 M - -
Net income 2021 -24,5 M - -
Net cash 2021 11,0 M - -
P/E ratio 2021 -2,20x
Yield 2021 -
Capitalization 53,8 M 53,8 M -
EV / Sales 2021 1 587x
EV / Sales 2022 1 901x
Nbr of Employees 23
Free-Float 93,1%
Chart REGULUS THERAPEUTICS INC.
Duration : Period :
Regulus Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGULUS THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 0,72 $
Average target price 1,17 $
Spread / Average Target 62,4%
EPS Revisions
Managers and Directors
Joseph P. Hagan President, Chief Executive Officer & Director
Crispina Calsada Chief Financial Officer
Stelios Papadopoulos Chairman
Denis Drygin Chief Scientific Officer
David Baltimore Independent Director
Sector and Competitors
1st jan.Capi. (M$)
REGULUS THERAPEUTICS INC.-46.79%52
MODERNA, INC.214.44%131 902
LONZA GROUP AG20.01%55 520
IQVIA HOLDINGS INC.35.73%46 608
CELLTRION, INC.-27.16%31 131
SEAGEN INC.-17.54%26 209